PBYI - Puma Biotechnology, Inc. - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Pharmaceutical Preparations - PBYI (1401667)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
29 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S7+1-1+4+0

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Price

Qty

Owned

ΔOwn

Value

1d

1w

1m

6m

2018-12-03
PBYIEyler Charles RSEE REMARKSS - Sale$22.77-1,23933,967-4%-$28,212
A
2018-01-22
PBYIEyler Charles RSEE REMARKSS - Sale$92.85-66928,027-2%-$62,117
2018-07-20
PBYILo StevenChief Commercial OfficerS - Sale$51.85-1,83923,523-7%-$95,360
2018-07-20
PBYIEyler Charles RSEE REMARKSS - Sale$51.95-61035,206-2%-$31,690
2018-07-20
PBYIBryce Richard PaulSEE REMARKSS - Sale$51.95-1,83632,543-5%-$95,381
2018-07-20
PBYIAuerbach Alan HPres, CEO, 10%S - Sale$52.00-12,5204,179,0610%-$651,020
2018-06-01
PBYIEyler Charles RSEE REMARKSS - Sale$53.00-1,21135,816-3%-$64,183
2018-01-22
PBYILo StevenChief Commercial OfficerS - Sale$92.85-1,85825,362-7%-$172,515
2018-01-22
PBYIEyler Charles RSEE REMARKSS - Sale$92.85-66928,027-2%-$62,117
2018-01-22
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale$92.75-1,86025,379-7%-$172,515
2018-01-22
PBYIAuerbach Alan HPres, CEO, 10%S - Sale$92.75-10,6924,155,9310%-$991,683
2017-12-01
PBYIEyler Charles RSEE REMARKSS - Sale$105.47-1,32228,696-4%-$139,424
D
2017-09-29
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale+OE$120.00-15,00027,239-36%-$1,800,000
DM
2017-09-06
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale+OE$100.09-15,00027,239-36%-$1,501,400
2017-07-20
PBYILo StevenChief Commercial OfficerS - Sale$94.90-1,99027,220-7%-$188,853
2017-07-20
PBYIEyler Charles RSEE REMARKSS - Sale$95.15-66230,018-2%-$62,991
2017-07-20
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale$94.48-1,99827,239-7%-$188,777
2017-07-20
PBYIAuerbach Alan HPres, CEO, 10%S - Sale$94.73-13,1754,166,6230%-$1,248,005
D
2017-07-03
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale+OE$87.10-5,00029,237-15%-$435,500
M
2017-06-08
PBYIAdage Capital Partners Gp, L.L.C.10%S - Sale$80.32-247,2607,550,882-3%-$19,858,910
M
2017-06-01
PBYIAdage Capital Partners Gp, L.L.C.10%S - Sale$87.84-507,1288,230,483-6%-$44,544,975
M
2017-05-24
PBYIAdage Capital Partners Gp, L.L.C.10%S - Sale$75.38-1,235,70010,087,636-11%-$93,144,268
2017-02-01
PBYICharnas RobertSee RemarksS - Sale$31.83-3,00826,453-10%-$95,7550+11+1
A
2017-01-20
PBYICharnas RobertSee RemarksS - Sale$33.24-2,23929,461-7%-$74,4130+11+1
2017-01-20
PBYILo StevenChief Commercial OfficerS - Sale$33.24-2,29029,210-7%-$76,108+2-6+5
2017-01-20
PBYIEyler Charles RSEE REMARKSS - Sale$33.24-8209,680-8%-$27,253+2-6+5
2017-01-20
PBYICharnas RobertSee RemarksS - Sale$33.24-2,29329,407-7%-$76,208+2-6+5
2017-01-20
PBYIBryce Richard PaulSVP, CLINICAL RESEARCH, DEVS - Sale$33.24-2,29329,237-7%-$76,208+2-6+5
2017-01-20
PBYIAuerbach Alan HPres, CEO, 10%S - Sale$33.24-10,2024,179,7980%-$339,064+2-6+5
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top